Inhibrx Gross Profit 2020-2022 | INBX
Inhibrx gross profit from 2020 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
| Inhibrx Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2021 | $7 |
| 2020 | $13 |
| 2019 | $13 |
| Inhibrx Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2022-03-31 | $1 |
| 2021-12-31 | $3 |
| 2021-09-30 | $3 |
| 2021-06-30 | $1 |
| 2021-03-31 | $1 |
| 2020-12-31 | $3 |
| 2020-09-30 | $6 |
| 2020-06-30 | $3 |
| 2020-03-31 | $1 |
| 2019-12-31 | |
| 2019-09-30 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.443B | $0.007B |
| Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.938B | 9.97 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.121B | 30.63 |
| QIAGEN (QGEN) | Netherlands | $10.718B | 16.92 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.276B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.228B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.817B | 46.07 |
| Emergent Biosolutions (EBS) | United States | $1.560B | 6.68 |
| Myovant Sciences (MYOV) | United Kingdom | $1.185B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.306B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.112B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.102B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.101B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.090B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
